CSIMarket


Oragenics Inc   (OGEN)
Other Ticker:  
 


 

Oragenics Inc

OGEN's Financial Statements and Analysis



Oragenics Inc increased second quarter of 2023 net loss per share of $-1.51 compare to net loss per share of $-0.03 recorded in the same quarter a year ago a decrease compare to $-1.41 realized in previous quarter.


second quarter of 2023
Earnings Per Share Revenues
$ -1.51 $  0 Mill
$-1.48     Unch.     -56.69 %



Oragenics Inc 's Revenue fell by -56.69 % in second quarter of 2023 (Jun 30 2023) year on year, to $0 million and declined by -22.68 % sequentially.


Oragenics Inc is Expected to report next financial results on April 13, 2024.

More on OGEN's Income Statement



Oragenics Inc 's in thesecond quarter of 2023 recorded net loss of $-3.051 million, an improvement compare to net loss of $-3.590 million in II. Quarter a year ago.

Sequentially net loss advanced

More on OGEN's Growth

Oragenics Inc Inventories
OGEN's Cash flow In the second quarter of 2023 company's net cash flow was $2 million


Oragenics Inc does not pay out common stock dividend.

In trailing twelve-month period Oragenics Inc payed $ -3.07 cash per share, on a free-cash flow basis .

Book value fell by -29.16 % sequentially to $3.58 per share, -49.68% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.80 per share from $ 4.27.

Company repurchased 0.00 million shares or 0.00 % in Jun 30 2023.


More on OGEN's Dividends

 Market Capitalization (Millions) 3
 Shares Outstanding (Millions) 2
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 14




Oragenics Inc does not pay out common stock dividend.

In trailing twelve-month period Oragenics Inc had negative $ -3.07 cash flow per share, on a free-cash flow basis .

Book value fell by -29.16 % sequentially to $3.58 per share, -49.68% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.80 per share from $ 4.27.

Company repurchased 0.00 million shares or 0.00 % in Jun 30 2023.


More on OGEN's Balance Sheets

 Market Capitalization (Millions) 3
 Shares Outstanding (Millions) 2
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 14
   


  News about Oragenics Inc Earnings

Oragenics Inc Faces Steep Decline and Industry Challenges In Second Quarter of 2023

Oragenics Inc, a major player in the pharmaceutical industry, recently announced a disastrous fiscal period with a significant decline in revenue and an expansion of net deficit per share. The company's revenue faded by a staggering -56.688% to just $0.01 million, while the net deficit per share expanded to $-1.51. This represents a significant setback compared to the corresponding reporting period from a year ago.
In contrast to Oragenics Inc's struggling performance, the rest of the Major Pharmaceutical Preparations sector has shown resilience and posted a 2.14% rise in top-line growth during the second quarter of 2023 compared to the same period in the previous year. This disparity highlights the chal...

Oragenics Inc Achieves Impressive Revenue Growth despite Reporting Major Losses in Recent Fiscal Period

Oragenics Inc is a Major Pharmaceutical Preparations company founded in 1996. The company is focused on developing novel antibiotics for the treatment of diseases caused by infectious agents, as well as other areas of unmet medical needs.
Despite an increase in revenue of 12.869% from the corresponding financial reporting period a year before, Oragenics Inc reported a loss per share of $-1.41. This is a significant change from the preceding financial reporting period where the company reported earnings of $0.00 million and a loss per share of $-0.02. In the most recent fiscal period, the company reported a net loss of $-2.845 million, as opposed to a deficit of $-4.591 million in the corresponding financ...


Date modified: 2023-08-21T10:26:18+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com